Displaying drugs 10151 - 10175 of 12433 in total
Bebtelovimab
Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. Bebtelovimab is notable in that the...
Investigational
Withdrawn
Matched Description: … (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of ... its expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2. ... It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing …
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … treatment of various immuno-inflammatory conditions. ... Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the ... While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are …
Iscalimab
Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
Investigational
Matched Description: … Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome). ... Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple …
DG051
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … ), an end product of the leukotriene pathway and a potent promoter of inflammation. ... of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. ... DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4 …
ABT-737
An inhibitor of members of the Bcl‑2 family of apoptosis regulators.
Investigational
Matched Description: … An inhibitor of members of the Bcl‑2 family of apoptosis regulators.[A252977] …
Gantenerumab
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large...
Investigational
Matched Description: … As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and ... Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological ... Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation …
XL281
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. ... Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell ... XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated …
Tideglusib
Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia...
Investigational
Withdrawn
Matched Description: … Alzheimer's disease as of 2012. ... Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for ... reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of …
KD7040
KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
Investigational
Matched Description: … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of …
Forasartan
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in...
Experimental
Matched Description: … , blockage of its effects results in a decreases in systemic vascular resistance. ... As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone …
ReN001
ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the...
Investigational
Matched Description: … ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable ... ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food ... and Drug Administration in the United States for consideration for the treatment of stroke in humans …
AZD7442
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that...
Investigational
Matched Description: … against COVID-19 - a significantly longer window of efficacy than that of other vaccines. ... [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection ... trials for the prevention and treatment of COVID-19. …
Biropepimut-S
Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity).
Investigational
Matched Description: … (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity ... Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 …
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Matched Description: … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic ... pathway of the blood coagulation system. ... as an anticoagulant for the treatment of thromboembolic disorders. …
Didesmethylrocaglamide
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... [A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears ... anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. …
Isatoribine
Isatoribine is a selective agonist of TLR7.
Investigational
Matched Description: … Isatoribine is a selective agonist of TLR7. …
NRP409
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Setiptiline
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … In Japan, the company Mochida started its commercialization for the treatment of depression started in …
ND7001
ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new...
Investigational
Matched Description: … It is the first representative of a new generation of psycho-active compounds potentially devoid of several ... It is a new type of antidepressant drug with anxiolytic activity. ... ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. …
CX501
Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by Cellerix and is in phase I of clinical trials.
Investigational
Matched Description: … the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus ... It is developed by Cellerix and is in phase I of clinical trials. ... is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of …
XEN-2174
XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET). NET is the primary mechanism regulating the biological effects of...
Investigational
Matched Description: … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation ... of inhibitory pathways preventing pain signals from reaching the brain. ... XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's …
Rozrolimupab
Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).
Investigational
Matched Description: … Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN). ... Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies ... to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic …
Dectrekumab
Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence).
Investigational
Matched Description: … of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence). ... Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification …
Managlinat dialanetil
CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Investigational
Matched Description: … enzymes of gluconeogenesis. ... CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting …
AX200
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
Matched Description: … stroke, while stimulating simultaneously the regeneration of nervous tissue through the induction of ... is halfway through the process of gaining clinical approval. ... neuro- and arteriogenesis and supporting the reorganisation of the nervous system. …
Displaying drugs 10151 - 10175 of 12433 in total